1 Global Inhalation Anesthesia Market Insight Analysis
The global inhalation anesthesia market is valued at USD 1,951.98 million in 2024, with an estimated market CAGR of 5.73% from 2024 to 2033.
Inhalation anesthesia refers to the administration of anesthetic agents through inhalation to induce and maintain general anesthesia. These agents are typically volatile liquids or gases that are delivered via specialized vaporizers or anesthesia machines. Inhalation anesthetics are preferred for their rapid onset of action, ease of administration, and the ability to control the depth of anesthesia precisely. They are widely used in various surgical procedures, from minor day-care surgeries to complex operations, ensuring that patients remain unconscious and free from pain.
Figure Global Inhalation Anesthesia Market Size (M USD) and CAGR (2024-2033)
2 Inhalation Anesthesia Market Growth Drivers and Restraints
As the global population ages, the number of people suffering from cancer, cardiovascular, spinal, orthopedic, respiratory, gastrointestinal, neurological and other diseases increases, and the prevalence of chronic diseases requiring surgical treatment increases. For example, the elderly is more susceptible to cardiovascular and neurodegenerative diseases and often require surgical intervention, which increases the number of surgeries and directly drives the growth of demand for inhaled anesthetics. At the same time, the increase in the number of surgeries such as ligament and other soft tissue repair in orthopedic surgery has further promoted the development of the inhaled anesthesia market.
Compared with intravenous anesthesia, inhaled anesthesia has significant advantages and has become the first choice for many medical practitioners. It can avoid excessive use of drugs, reduce drug accumulation in the body, reduce drug toxicity, and be discharged through the lungs, with little effect on the patient’s autonomic nervous function. In addition, inhaled anesthesia has a lower risk of delirium and is more cost-effective. These advantages make it more competitive in the market and promote market growth.
The rapid development of technology has injected vitality into the inhaled anesthesia market. The emergence of new evaporators can accurately control the concentration and delivery rate of anesthetic gases, improve the anesthesia effect, and reduce the recovery time of patients. At the same time, the combination of inhalation anesthesia and mobile recovery units (MRUs) can provide patients with effective analgesia and sedation after surgery or endoscopic examinations, expanding the application scenarios of inhalation anesthesia and stimulating market demand.
The economic and medical conditions in different regions have different impacts on the inhalation anesthesia market. As the market leader, the United States has increased government funding for the research and development of new inhalation anesthesia, and the incidence of diseases such as cancer has increased, which has jointly driven market growth. China is expected to become the fastest growing market due to economic development, increased demand for medical infrastructure, an increase in the number of hospitals, increased R&D investment, advancement of medical reforms, and technological progress.
The large-scale use of inhalation anesthetics brings environmental risks. Its emissions may pose potential risks to the health of operating room personnel and urban residents, and will also indirectly affect global climate change due to the greenhouse effect. Although there are exhaust gas removal systems, the technology is lagging behind and these gases cannot be effectively captured and treated, limiting the further expansion of the market.
The FDA’s strict supervision of drug approval and surgical procedures has led to a decline in drug approval rates and increased the difficulty of new products entering the market. For example, the number of drug applications rejected by the FDA has increased in recent years, which has made the research and development and promotion of inhaled anesthetics face greater obstacles and restricted the innovation and development of the market.
Inhaled anesthetics have side effects and are less used in certain surgeries. At the same time, the patents of halogenated anesthetics have expired one after another, triggering competition from generic drugs, resulting in fierce market price competition, compressing corporate profit margins, and having a certain impact on the stable development of the market.
3 Technological Innovations in the Inhalation Anesthesia Market
Technological advances have led to the emergence of new vaporizers in the field of inhalation anesthesia, which can accurately control the concentration and release rate of anesthetic gases to meet the personalized needs of different patients. Compared with traditional drug delivery methods such as masks, new vaporizers significantly improve the accuracy and safety of anesthesia, effectively reduce the patient’s recovery time, thereby improving the quality and efficiency of medical services and promoting the development of the inhalation anesthesia market.
The combination of inhalation anesthesia and mobile recovery units (MRUs) is a major innovation highlight. This combination enables patients to obtain effective pain relief and sedation services in a timely manner after surgery or endoscopic examinations, greatly expanding the application scenarios of inhalation anesthesia, bringing new growth points to the market, and meeting more diverse medical needs.
In terms of raw materials, although most chemical raw materials are in sufficient supply, the requirements for raw material quality and supply stability are constantly increasing. At the same time, the manufacturing process is continuously optimized to improve product quality and production efficiency. For example, in the synthesis of sevoflurane, the process is continuously improved to improve its purity and stability to ensure the safety and effectiveness of the product.
In 2021, Baxter International acquired Hillrom for a total price of approximately US$12.4 billion (including debt). Hillrom has a complementary product portfolio and innovative product lines. This acquisition enables Baxter to provide a wider range of medical products and services to patients and clinicians around the world, accelerate its expansion in digital and connected care solutions, enhance Baxter’s competitiveness in the medical market, and also have an impact on the competitive landscape of the inhalation anesthesia market.
In 2020, AbbVie completed the acquisition of Allergan for approximately US$63 billion. This acquisition has expanded AbbVie’s business areas and enriched its product range. Although the acquisition is not directly aimed at the inhalation anesthesia business, it has enhanced the company’s overall strength and enabled it to have stronger resources and capabilities in the competition in the inhalation anesthesia market.
4 Global Inhalation Anesthesia Market Size by Type
Sevoflurane is the most widely used inhalation anesthetic due to its favorable properties, such as rapid onset of action, minimal irritation, and suitability for both induction and maintenance of anesthesia. In 2024, the market revenue for Sevoflurane is projected to reach $1,408.48 million USD, accounting for approximately 72.16% of the total market share. This dominant position is attributed to its versatility and safety profile, making it a preferred choice for a wide range of surgical procedures.
Isoflurane is another significant player in the inhalation anesthesia market. It is known for its stability and effectiveness in maintaining anesthesia, particularly in patients with cardiovascular conditions. In 2024, Isoflurane is expected to generate a market revenue of $183.33 million USD, representing about 9.39% of the total market share. Its use is more specialized compared to Sevoflurane, often reserved for specific surgical needs and patient conditions.
Desflurane is recognized for its rapid recovery times and minimal side effects, making it ideal for certain surgical procedures where quick patient turnover is required. In 2024, the market revenue for Desflurane is forecasted to be $360.17 million USD, capturing around 18.45% of the total market share. Its higher cost and specialized equipment requirements limit its widespread use but ensure its importance in specific surgical settings.
Table Global Inhalation Anesthesia Market Size and Share by Type in 2024
Type | Market Size (M USD) 2024 | Market Share 2024 |
|---|---|---|
Sevoflurane | 1408.48 | 72.16% |
Isoflurane | 183.33 | 9.39% |
Desflurane | 360.17 | 18.45% |
5 Global Inhalation Anesthesia Market Size by Application
For the induction application, which is crucial for initiating the anesthesia process before surgeries and medical procedures, the market revenue is expected to reach approximately 308.30 million US dollars. This accounts for about 15.79% of the total market revenue. The induction stage requires a higher concentration of anesthetic drugs to quickly induce a state of unconsciousness and prepare patients for subsequent procedures.
The growth of the induction segment is driven by the increasing number of surgical operations globally. As more surgeries are being performed, the demand for effective induction agents like inhalation anesthesia continues to rise. For example, in orthopedic surgeries, which are on the increase due to the aging population and sports – related injuries, a reliable induction method is essential, and inhalation anesthesia offers advantages such as rapid onset and relatively low risk of side – effects.
The maintenance application, on the other hand, has a significantly larger market share. In 2024, the revenue for the maintenance segment of inhalation anesthesia is projected to be around 1643.69 million US dollars, representing about 84.21% of the total market revenue. Maintenance anesthesia is used to keep patients in a controlled sedated state during surgeries.
This application is more extensive in terms of usage volume as surgeries can vary greatly in duration, and a continuous supply of anesthesia is required to ensure patient comfort and immobility. In complex surgeries like cardiac and neurological procedures, which can last for several hours, the demand for maintenance inhalation anesthesia is particularly high. The stability and effectiveness of inhalation anesthesia in maintaining the proper depth of anesthesia make it a preferred choice for many surgeons.
Table Global Inhalation Anesthesia Market Size and Share by Application in 2024
Application | Market Size (M USD) 2024 | Market Share 2024 |
|---|---|---|
Induction | 308.30 | 15.79% |
Maintenance | 1643.69 | 84.21% |
6 Global Inhalation Anesthesia Market Size by Region
The United States has been a major player in the inhalation anesthesia market. In 2024, its market revenue is expected to be around 735.38 million US dollars. The US has a highly developed healthcare system with a large number of hospitals and surgical centers. The high prevalence of chronic diseases like cancer and cardiovascular diseases leads to a substantial demand for surgical procedures, thus driving the consumption of inhalation anesthesia. Moreover, the government’s investment in medical research and development, as well as the presence of advanced medical technology, contribute to the growth of the inhalation anesthesia market in the country. However, the market in the US also faces challenges such as high competition among manufacturers and strict regulatory requirements.
Europe is another important market for inhalation anesthesia. In 2024, the market revenue in Europe is projected to be approximately 456.95 million US dollars. The region has a well – established healthcare infrastructure, and countries like Germany, the UK, and France have a significant share in the market. The demand for inhalation anesthesia in Europe is driven by the aging population and the increasing number of elective surgeries. For example, in Germany, the high – quality healthcare services attract patients from neighboring countries, which further boosts the demand for inhalation anesthesia. However, the European market is also affected by economic fluctuations and the complex regulatory environment across different countries.
China is an emerging and rapidly growing market in the global inhalation anesthesia landscape. In 2024, the market revenue in China is expected to reach about 474.6 million US dollars. The growth in China can be attributed to multiple factors. The continuous economic development has led to an improvement in healthcare infrastructure, with more hospitals being built and equipped with advanced medical facilities. The increasing awareness of healthcare among the population and the rising incidence of diseases that require surgical treatment, such as cancer and respiratory disorders, are fueling the demand for inhalation anesthesia. Additionally, the government’s support for the healthcare industry and the development of domestic pharmaceutical companies are also contributing to the market’s growth.
Japan, with its advanced medical technology and high – quality healthcare services, has a stable market for inhalation anesthesia. In 2024, the market revenue in Japan is estimated to be around 58.86 million US dollars. The country’s aging population and high – standard medical care requirements ensure a consistent demand for inhalation anesthesia. However, Japan’s market growth may be limited by its relatively small population size compared to other major markets and the slow – down in its overall economic growth.
Figure Global Inhalation Anesthesia Market Size (M USD) by Region in 2024
7 Global Inhalation Anesthesia Market Analysis by Major Players
7.1 Baxter
Company Introduction and Business Overview:
Baxter International Inc. is a leading global healthcare company headquartered in Deerfield, Illinois, USA. Established in 1931, Baxter has a long history of innovation and excellence in the medical products and pharmaceuticals sector. The company is renowned for its comprehensive portfolio of products, including intravenous solutions, anesthesia agents, and renal care products.
Baxter’s business is focused on improving the lives of patients through the development and delivery of essential healthcare products. The company operates in several key areas, including acute care, anesthesia, and renal care. Baxter’s commitment to innovation and quality has made it a trusted partner for healthcare providers worldwide.
Products:
Baxter offers a wide range of inhalation anesthesia products, including desflurane, which is used for the induction and maintenance of general anesthesia. The company’s desflurane product is known for its rapid onset and offset, making it suitable for a variety of surgical procedures.
Market Performance in 2022:
Baxter’s revenue in 2022 was $769.29 million USD with a gross margin of $369.34 million USD (48.01%).
7.2 AbbVie Inc.
Company Introduction and Business Overview:
AbbVie Inc. is a global biopharmaceutical company that was spun off from Abbott Laboratories in 2013. Headquartered in North Chicago, Illinois, USA, AbbVie focuses on the research, development, and commercialization of advanced pharmaceutical products. The company is known for its innovative approach to addressing complex medical challenges.
AbbVie’s business strategy is centered on driving scientific innovation to develop and deliver transformative medicines. The company operates in several therapeutic areas, including immunology, oncology, and neuroscience. AbbVie’s commitment to research and development has positioned it as a leader in the global pharmaceutical market.
Products:
AbbVie offers sevoflurane, a widely used inhalation anesthetic for the induction and maintenance of general anesthesia. The company’s sevoflurane product is known for its low blood-gas partition coefficient, which allows for rapid induction and recovery.
Market Performance in 2022:
AbbVie Inc. reported a revenue of $406.30 million USD and a gross margin of $192.10 million USD (47.28%).
7.3 Jiangsu Hengrui Medicine Co. Ltd.
Company Introduction and Business Overview:
Jiangsu Hengrui Medicine Co. Ltd. is a leading pharmaceutical company based in China. Established in 1970, Hengrui has grown to become a significant player in the global healthcare industry. The company is known for its innovative approach to drug development and its focus on high-quality products.
Hengrui’s business is centered on the development and production of anti-tumor drugs, surgical medications, and imaging interventional products. The company’s commitment to innovation and quality has made it a trusted supplier in the global pharmaceutical market. Hengrui’s extensive R&D capabilities and strategic partnerships have positioned it as a leader in the industry.
Products:
Hengrui offers desflurane, an inhalation anesthetic used for the maintenance of general anesthesia. The company’s desflurane product is known for its rapid onset and offset, making it suitable for a variety of surgical procedures.
Market Performance in 2022:
Jiangsu Hengrui Medicine Co. Ltd. achieved a revenue of $180.18 million USD with a gross margin of $129.10 million USD (71.65%).